The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Open accessAbstract
Objective: To examine interactions of apolipoprotein E ( APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging. Methods: Two hundred forty‐one cognitively normal individuals, aged 45–88 years, had cerebral amyloid imaging studies with Pittsburgh Compound‐B (PIB). Of the 241 individuals, 168 (70%) also had cerebrospinal fluid (CSF) assays of amyloid‐beta 42 (Aβ 42 ), tau, and phosphorylated tau (ptau 181 ). All individuals were genotyped for APOE . Results: The frequency of individuals with elevated mean cortical binding potential (MCBP) for PIB rose in an age‐dependent manner from 0% at ages 45–49 years to 30.3% at 80–88 years. Reduced levels of CSF Aβ 42 appeared to begin earlier (18.2% of those aged 45–49 years) and increase with age in higher frequencies (50% at age 80–88 years) than elevations of MCBP. There was a gene dose effect for the APOE4 genotype, with greater MCBP increases and greater reductions in CSF Aβ 42 with increased numbers of APOE4 alleles. Individuals with an APOE2 allele had no increase in MCBP with age and had higher CSF Aβ 42 levels than individuals without an APOE2 allele. There was no APOE4 or APOE2 effect on CSF tau or ptau 181 . Interpretation: Increasing cerebral Aβ deposition with age is the pathobiological phenotype of APOE4 . The biomarker sequence that detects Aβ deposition may first be lowered CSF Aβ 42 , followed by elevated MCBP for PIB. A substantial proportion of cognitively normal individuals have presumptive preclinical AD. ANN NEUROL 2010;67:122–131
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE status has been found to modulate the onset of extracellular amyloid plaque deposition, one of the key pathognomonic features of the disease (6, 7).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“On the basis of previous studies (7, 27), individuals with mean cortical binding potential (MCBP) for PIB >0.18 were considered PIB-positive (PIB+).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Increasing age and ApoE genetic background are the strongest known risk factors for AD and plaque load (33, 48); thus it was critical that these parameters were controlled.”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Sex differences in Aβ burden alone have not been reported in older adults,11–13”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [13]
In the citing paper
“Previous cross-sectional studies indicate that Aβ42 levels decrease in the CSF as Aβ starts to accumulate, before fibrillar plaques can be detected with PET7–11.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,345
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Flagged first, then by citations
1 of the 80 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–835 of 835
Xu, L., Ren, C., Jing, C., Wang, G., Wei, H., Kong, M., Ba, M., & Initiative, A. D. N. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16376
Sampatakakis, S. N., Mourtzi, N., Charisis, S., Kalligerou, F., Mamalaki, E., Ntanasi, E., Hatzimanolis, A., Koutsis, G., Ramı́rez, A., Lambert, J., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051053
Reducing CETP activity prevents memory decline in an Alzheimer’s disease mouse model
Phénix, J., Sarty, I. M., Katz, M. S., Cobá, A. V., Marure-Rojano, A. E., Nie, H., Kerksiek, A., Jerry, I., Berger, C. S., Kiss, R. S., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00482-w · Cited by 3
Associations Between Walking Pace, APOE-ε4 Genotype, and Brain Health in Middle-Aged to Older Adults
Aslan, D. H., Sayre, M. K., Bharadwaj, P. K., Ally, M., Maltagliati, S., Lai, M. H. C., Wilcox, R. R., Klimentidis, Y. C., Alexander, G. E., & Raichlen, D. A. (2025) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003646
Apolipoprotein E4 Carriers as Clinical Trial Subjects
Smith, C. J., Ashford, J. W., & Perfetti, T. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_63-1
Indenkleef, L. S. A. (2015) · Utrecht University Repository (Utrecht University)
Hsieh, Y.-C., Negri, J., He, A., Pearse, R. V., Liu, L., Duong, D. M., Chibnik, L. B., Bennett, D. A., Seyfried, N. T., & Young‐Pearse, T. L. (2022) · Figshare · doi:10.6084/m9.figshare.21185049
Baek, M. S., Cho, H., Lee, H. S., Lee, J. H., Ryu, Y. H., & Lyoo, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13174043
Ma, L.-Z., Tan, L., Bi, Y.-L., Shen, X.-N., Xu, W., Ma, Y.-H., Li, H.-Q., Dong, Q., & Yu, J.-T. (2020) · Figshare · doi:10.6084/m9.figshare.12114753
Huang, Y.-M., Ma, Y.-H., Gao, P.-Y., Wang, Z.-B., Huang, L., Hou, J.-H., Tan, L., & Yu, J.-T. (2023) · Figshare · doi:10.6084/m9.figshare.22619233
Ali, M., Archer, D. B., Gorijala, P., Western, D., Timsina, J., Fernandez, M., Wang, T.-C., Satizábal, C. L., Yang, Q., Beiser, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26585304
Self-citationAndersson, E., Schultz, N., Saito, T., Saido, T. C., Blennow, K., Gouras, G. K., Zetterberg, H., & Hansson, O. (2023) · Figshare · doi:10.6084/m9.figshare.22620482
APOE, Human Ancestry, and Evolution
Smith, C. J., Ashford, J. W., & Perfetti, T. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_4-1
APOE, Biomarkers, and Proteogenomics in Alzheimer’s Disease
Pereira, J. D., Tosatti, J. A. G., & Gomes, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-52641-1_66-1
A Review of Interaction Between Sleep Apnea and APOE e4 on the Risk of Dementia
Ding, X., Watwood, C., Patel, A., Hegde, K., Mahanna, B., Escudero, L., & Neils-Strunjas, J. (2026) · Journal of Gerontology and Geriatrics · doi:10.3390/jgg74010004
Ashford, J. W., Smith, C. J., & Oriá, R. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-52641-1_83-1
Wang, X., Zhang, C., Liu, X., Tai, Y., Ma, G., Kong, M., Ba, M., & Initiative, A. D. N. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261435429
Mahmoudi, A.-E.-R. (2015) · theses.fr (ABES) · doi:10.70675/5f05520ez1713z4991za6c8z055ab117e2bb
Tomadesso, C. (2018) · theses.fr (ABES) · doi:10.70675/7fad6418zff81z49c7z984dz63aa2e44d7fc
Lombardo, D. (2021) · theses.fr (ABES) · doi:10.70675/ccfa1de2z5623z4c5dz8349z154225e4164d
Die Amyloid-Forschung zieht weitere Kreise und nimmt Fahrt auf
Behl, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72210-7_14
APOE, Biomarkers, and Proteogenomics in Alzheimer’s Disease
Pereira, J. D., Tosatti, J. A. G., & Gomes, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_66
Ashford, J. W., Smith, C. J., & Oriá, R. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_83
Rizzo, M., Oomens, J. E., Jansen, W. J., Visser, P. J., & Vos, S. J. B. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261453099 · Cited by 1
Age-related modulation of γ-secretase activity in non-human primate brains.
西村, 正., 中村, 紳., 遠山, 育., NISHIMURA, M., NAKAMURA, S., Kimura, N., Lei, L. I. U., Suzuki, T., & Tooyama, I. (n.d.) · Institutional Repositories DataBase (IRDB)
An investigation of the APOE4 association with tau pathology and cognitive decline
Peretti, D. E., Boccalini, C., Ribaldi, F., Mendes, A. J., Blouin, J., Wyss‐Dominguez, C., Margot, H., Treyer, V., Gietl, A. F., Höck, C., et al. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100231
Lista, S., Filippi, L., Emanuele, E., López‐Ortiz, S., Cisale, G. Y., Minoretti, P., Garaci, F. G., & Santos‐Lozano, A. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00879-w
Potential links between PCOS/PMOS and Alzheimer disease and related dementias
Amiri, M., Hamidi, A. K., Farkas, D. L., Buyalos, R. P., & Azziz, R. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag206
Early Prognosis of Alzheimer's Disease: Diagnostic Biomarker Review Article
Maghmomeh, A., Alkhoder, L., Turk, B., Habbal, A., & AL-Afandi, D. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00688
Martinez-Lage, P., Solje, E., Martins, J. G., Guess, M., & Sarkar, S. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01056-1
Metadata
- Authors
- Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Morris, John C.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 67
- Issue
- 1
- Pages
- 122-131
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2830375
- OpenAlex
- W2014897304
- Cited by
- 830
- References
- 80
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 38 · 2023: 39 · 2022: 54 · 2021: 40 · 2020: 53 · 2019: 53 · 2018: 49 · 2017: 58 · 2016: 54 · 2015: 48 · 2014: 65 · 2013: 76 · 2012: 63
- FWCI
- 32.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000448)
- National Institute on Aging (P50AG005681, P01AG003991, P01AG026276)
- National Center for Research Resources (UL1RR024992)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- apolipoprotein E, APOE ε4, APOE2, amyloid-beta, tau protein, preclinical Alzheimer's disease, Pittsburgh compound B, cerebrospinal fluid biomarkers, gene dosage effect, phosphorylated tau
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Aniline Compounds, Apolipoproteins E, Brain, Female, Follow-Up Studies, Genotype, Humans, Longitudinal Studies, Male, Middle Aged, Peptide Fragments, Phosphorylation, Thiazoles, Amyloid beta-Peptides, tau Proteins, Apolipoprotein E4, Apolipoprotein E2, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
